US Stock MarketDetailed Quotes

SCNI Scinai Immunotherapeutics

Watchlist
  • 3.730
  • -0.190-4.85%
Close Aug 30 16:00 ET
  • 3.730
  • 0.0000.00%
Post 20:01 ET
3.12MMarket Cap0.00P/E (TTM)

Scinai Immunotherapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
68.34%-1.76M
-282.98%-1.46M
-29.14%-9.38M
-106.58%-1.23M
-16.82%-2.22M
-85.28%-5.55M
65.43%-382K
2.17%-7.27M
67.91%-593K
1.01%-1.9M
Net income from continuing operations
38.28%-2.32M
38.58%-2.16M
-12.15%-6.5M
54.46%-2.33M
-34.97%3.11M
-1.63%-3.76M
-42.02%-3.52M
29.37%-5.8M
-688.08%-5.12M
270.08%4.78M
Operating gains losses
--3K
---96K
---4.14M
---216K
---591K
----
----
----
----
----
Depreciation and amortization
237.41%496K
13.04%156K
-8.54%514K
-54.35%84K
46.46%145K
-34.40%147K
2.99%138K
19.32%562K
294.67%184K
-47.91%99K
Other non cash items
-95.13%226K
169.66%225K
110.27%401K
-73.12%770K
32.50%-4.69M
1,308.71%4.64M
-236.29%-323K
-23.86%-3.9M
217.14%2.87M
-1,140.87%-6.95M
Change In working capital
60.75%-303K
-43.44%220K
-393.73%-796K
-98.70%14K
-158.79%-427K
-256.66%-772K
-24.32%389K
-61.51%271K
220.64%1.08M
-134.98%-165K
-Change in receivables
-19.70%-158K
6.43%149K
-307.14%-290K
-572.73%-208K
-373.68%-90K
-2,595.95%-132K
13.82%140K
137.29%140K
-67.94%44K
-105.04%-19K
-Change in payables and accrued expense
77.43%-144K
-73.08%70K
-466.42%-491K
-78.45%223K
-128.57%-336K
40.85%-638K
-33.33%260K
-79.29%134K
338.88%1.04M
-839.61%-147K
-Change in other current assets
5,600.00%114K
516.67%75K
-71.90%43K
-65.03%57K
--2K
--2K
-128.57%-18K
3.38%153K
--163K
--0
-Change in other current liabilities
-2,775.00%-115K
-1,157.14%-74K
62.82%-58K
65.06%-58K
-400.00%-3K
-100.25%-4K
111.29%7K
-4.00%-156K
88.25%-166K
-98.66%1K
Cash from discontinued investing activities
Operating cash flow
38.87%-1.76M
52.17%-1.46M
-29.14%-9.38M
-106.58%-1.23M
-16.82%-2.22M
4.04%-2.88M
-176.83%-3.06M
2.17%-7.27M
67.91%-593K
1.01%-1.9M
Investing cash flow
Cash flow from continuing investing activities
98.41%-6K
66.67%-2K
23.80%-637K
13.33%-234K
75.00%-20K
-1,458.29%-377K
98.85%-6K
-501.44%-836K
-153.78%-270K
-1,881.57%-80K
Net PPE purchase and sale
98.41%-6K
66.67%-2K
23.80%-637K
13.33%-234K
75.00%-20K
-2,874.92%-377K
98.85%-6K
-501.44%-836K
-175.49%-270K
-6,340.10%-80K
Cash from discontinued investing activities
Investing cash flow
98.41%-6K
66.67%-2K
23.80%-637K
13.33%-234K
75.00%-20K
-1,458.29%-377K
98.85%-6K
-501.44%-836K
-153.78%-270K
-1,881.57%-80K
Financing cash flow
Cash flow from continuing financing activities
12K
1.42M
-83.97%1.09M
0
1.09M
0
0
-68.38%6.78M
-23.41%6.78M
Net common stock issuance
----
----
-85.09%139K
----
----
----
----
-95.65%932K
----
----
Proceeds from stock option exercised by employees
--12K
--1.42M
-83.80%947K
-102.38%-139K
--1.09M
--0
--0
--5.84M
--5.84M
----
Cash from discontinued financing activities
Financing cash flow
--12K
--1.42M
-83.97%1.09M
--0
--1.09M
--0
--0
-68.38%6.78M
-23.41%6.78M
--0
Net cash flow
Beginning cash position
-54.55%4.97M
-64.76%5.01M
-18.85%14.22M
-23.24%6.48M
-33.19%7.63M
-22.40%10.93M
-18.85%14.22M
469.29%17.52M
-21.55%8.45M
-13.46%11.42M
Current changes in cash
42.42%-1.87M
98.56%-44K
-574.19%-8.93M
-124.66%-1.46M
41.93%-1.16M
-3.07%-3.25M
-88.50%-3.07M
-109.56%-1.33M
-14.11%5.92M
34.72%-1.99M
Effect of exchange rate changes
395.12%121K
--0
86.24%-272K
90.73%-14K
100.71%7K
-109.06%-41K
37.60%-224K
-443.83%-1.98M
48.68%-151K
-260.76%-987K
End cash Position
-57.89%3.21M
-54.55%4.97M
-64.76%5.01M
-64.76%5.01M
-23.24%6.48M
-32.91%7.63M
-29.65%10.93M
-18.85%14.22M
-18.85%14.22M
-21.55%8.45M
Free cash flow
45.77%-1.76M
52.20%-1.47M
-23.68%-10.02M
-69.06%-1.46M
-13.12%-2.24M
-8.08%-3.25M
-88.50%-3.07M
-7.09%-8.1M
55.66%-863K
-3.09%-1.98M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 68.34%-1.76M-282.98%-1.46M-29.14%-9.38M-106.58%-1.23M-16.82%-2.22M-85.28%-5.55M65.43%-382K2.17%-7.27M67.91%-593K1.01%-1.9M
Net income from continuing operations 38.28%-2.32M38.58%-2.16M-12.15%-6.5M54.46%-2.33M-34.97%3.11M-1.63%-3.76M-42.02%-3.52M29.37%-5.8M-688.08%-5.12M270.08%4.78M
Operating gains losses --3K---96K---4.14M---216K---591K--------------------
Depreciation and amortization 237.41%496K13.04%156K-8.54%514K-54.35%84K46.46%145K-34.40%147K2.99%138K19.32%562K294.67%184K-47.91%99K
Other non cash items -95.13%226K169.66%225K110.27%401K-73.12%770K32.50%-4.69M1,308.71%4.64M-236.29%-323K-23.86%-3.9M217.14%2.87M-1,140.87%-6.95M
Change In working capital 60.75%-303K-43.44%220K-393.73%-796K-98.70%14K-158.79%-427K-256.66%-772K-24.32%389K-61.51%271K220.64%1.08M-134.98%-165K
-Change in receivables -19.70%-158K6.43%149K-307.14%-290K-572.73%-208K-373.68%-90K-2,595.95%-132K13.82%140K137.29%140K-67.94%44K-105.04%-19K
-Change in payables and accrued expense 77.43%-144K-73.08%70K-466.42%-491K-78.45%223K-128.57%-336K40.85%-638K-33.33%260K-79.29%134K338.88%1.04M-839.61%-147K
-Change in other current assets 5,600.00%114K516.67%75K-71.90%43K-65.03%57K--2K--2K-128.57%-18K3.38%153K--163K--0
-Change in other current liabilities -2,775.00%-115K-1,157.14%-74K62.82%-58K65.06%-58K-400.00%-3K-100.25%-4K111.29%7K-4.00%-156K88.25%-166K-98.66%1K
Cash from discontinued investing activities
Operating cash flow 38.87%-1.76M52.17%-1.46M-29.14%-9.38M-106.58%-1.23M-16.82%-2.22M4.04%-2.88M-176.83%-3.06M2.17%-7.27M67.91%-593K1.01%-1.9M
Investing cash flow
Cash flow from continuing investing activities 98.41%-6K66.67%-2K23.80%-637K13.33%-234K75.00%-20K-1,458.29%-377K98.85%-6K-501.44%-836K-153.78%-270K-1,881.57%-80K
Net PPE purchase and sale 98.41%-6K66.67%-2K23.80%-637K13.33%-234K75.00%-20K-2,874.92%-377K98.85%-6K-501.44%-836K-175.49%-270K-6,340.10%-80K
Cash from discontinued investing activities
Investing cash flow 98.41%-6K66.67%-2K23.80%-637K13.33%-234K75.00%-20K-1,458.29%-377K98.85%-6K-501.44%-836K-153.78%-270K-1,881.57%-80K
Financing cash flow
Cash flow from continuing financing activities 12K1.42M-83.97%1.09M01.09M00-68.38%6.78M-23.41%6.78M
Net common stock issuance ---------85.09%139K-----------------95.65%932K--------
Proceeds from stock option exercised by employees --12K--1.42M-83.80%947K-102.38%-139K--1.09M--0--0--5.84M--5.84M----
Cash from discontinued financing activities
Financing cash flow --12K--1.42M-83.97%1.09M--0--1.09M--0--0-68.38%6.78M-23.41%6.78M--0
Net cash flow
Beginning cash position -54.55%4.97M-64.76%5.01M-18.85%14.22M-23.24%6.48M-33.19%7.63M-22.40%10.93M-18.85%14.22M469.29%17.52M-21.55%8.45M-13.46%11.42M
Current changes in cash 42.42%-1.87M98.56%-44K-574.19%-8.93M-124.66%-1.46M41.93%-1.16M-3.07%-3.25M-88.50%-3.07M-109.56%-1.33M-14.11%5.92M34.72%-1.99M
Effect of exchange rate changes 395.12%121K--086.24%-272K90.73%-14K100.71%7K-109.06%-41K37.60%-224K-443.83%-1.98M48.68%-151K-260.76%-987K
End cash Position -57.89%3.21M-54.55%4.97M-64.76%5.01M-64.76%5.01M-23.24%6.48M-32.91%7.63M-29.65%10.93M-18.85%14.22M-18.85%14.22M-21.55%8.45M
Free cash flow 45.77%-1.76M52.20%-1.47M-23.68%-10.02M-69.06%-1.46M-13.12%-2.24M-8.08%-3.25M-88.50%-3.07M-7.09%-8.1M55.66%-863K-3.09%-1.98M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion with Explanatory Notes--------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg